BioSpace News Archive

Johnson & Johnson announced that Paula A. Johnson, MD, MPH, President of Wellesley College, has been appointed to its Board of Directors.

Precision Optics Corporation, Inc. (NASDAQ: POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense industries, announced operating results on an unaudited basis for its second quarter fiscal year 2023.

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) today announced financial results for its third fiscal quarter and nine months ended December 31, 2022.

Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) (“Theratechnologies”), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will report financial results for its fourth quarter and full year fiscal 2022 ended November 30, on Tuesday, February 28, 2023.

Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult to treat cancers, announced that the Company will report fourth quarter and full year 2022 financial results on Thursday, February 23, 2023, after market close.

Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced the following update on its currently enrolling open-label Phase 1b camsirubicin Maximum Tolerated Dose (MTD) trial in patients with advanced soft tissue sarcoma (ASTS).

Huntsville, Alabama-based technology company Curiteva announces the first FDA 510(k) cleared 3D-printed PEEK implant, the Inspire Porous PEEK Cervical Interbody System with HAFUSE Technology.

Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT) today announced that the first patient has been dosed in the randomized part of the open label Phase 2 clinical trial evaluating CM24 in the treatment of advanced metastatic pancreatic cancer (PDAC).

Quest Diagnostics and NewYork-Presbyterian announced a strategic agreement designed to broaden access to quality, innovative laboratory services for the providers and patients of NewYork-Presbyterian primarily in New York as well as the Tri-State Area and beyond.

Bio-Techne Corporation and Cell Signaling Technology announced the addition of Simple Western™ validation to CST antibodies.